Sattar, Naveed http://orcid.org/0000-0002-1604-2593
McGuire, Darren K.
Pavo, Imre
Weerakkody, Govinda J.
Nishiyama, Hiroshi
Wiese, Russell J.
Zoungas, Sophia http://orcid.org/0000-0003-2672-0949
Article History
Received: 15 November 2021
Accepted: 19 January 2022
First Online: 24 February 2022
Competing interests
: N.S. has consulted for or received lecture fees from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer and Sanofi and received grant support from AstraZeneca, Boehringer Ingelheim, Novartis and Roche Diagnostics through his institution, the University of Glasgow. D.K.M. reports personal fees from Boehringer Ingelheim, Janssen Research and Development, Sanofi US, Merck & Co., Merck Sharp & Dohme, Eli Lilly and Company, Novo Nordisk, GlaxoSmithKline, AstraZeneca, Lexicon Pharmaceuticals, Eisai, Pfizer, Metavant, Applied Therapeutics, Afimmune, Bayer and Esperion. S.Z. reports participation in advisory boards, expert committees or educational meetings on behalf of Monash University for Eli Lilly and Company, Boehringer Ingelheim, Sanofi, Servier, AstraZeneca, Novo Nordisk and Merck Sharp & Dohme Australia, outside of the submitted work. N.S., D.K.M. and S.Z. sit on the steering committee for the SURPASS-CVOT. I.P., R.J.W., G.J.W. and H.N. are employees and shareholders of Eli Lilly and Company.